PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of muscle function in patients in a randomized clinical trial designed to keep the drug on the market in Europe.
But a separate analysis of the same study data that might allow PTC to seek approval in the U.S. failed to reach statistical significance.
Shares of PTC rose 18% to $33 in early Tuesday trading.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect